FDA Approves Apalutamide (Erleada); the first treatment for non-metastatic castration-resistant prostate cancer (READ MORE HERE).
Approximately 30% of patients treated for what..
Neha Vapiwala, MD:
University of Pennsylvania – Philadelphia, PA
Alan Wein, MD, PhD, Professor and Chair of the Division of Urology, University of Pennsylvania School of Medicine and Chief of Urology at the Hospital of the University of Pennsylvania.
Understanding the molecules and mechanisms that contribute..
Andreas Varkaris, MD:
The University of Texas MD Anderson Cancer Center
Gary Gallick, PhD and Christopher Logothetis, MD
Executive Director, Programs
President, Samaritan Health Initiatives, Inc.
Former Commissioner, Food and Drug Administration
Former Director, National Cancer Institute
Senior Fellow, Milken Institute